LMR Partners’s ProQR Therapeutics PRQR Stock Holding History

LMR Partners’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-109,824	Closed	-$99K	–	1426
2022 Q1	$99K	Buy	+109,824	New	+$368K	﹤0.01%	1183

Other funds holding PRQR

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

LMR Partners's PRQR Position: Q2 2022 in Review

LMR Partners sold out of ProQR Therapeutics (PRQR) in Q2 2022, closing a stake of 109,824 shares — an estimated $99K sold.

LMR Partners first reported a position in PRQR in Q1 2022 and held it in 1 quarter. The position peaked at $99K in Q1 2022. 51 funds tracked by Wall St. Rank hold PRQR as of Q2 2022.

LMR Partners reported no remaining ProQR Therapeutics position as of Q2 2022 after selling out during the quarter.
LMR Partners sold 109,824 ProQR Therapeutics shares in Q2 2022, an estimated $99K.
LMR Partners first reported a position in ProQR Therapeutics in Q1 2022 and held it in 1 quarter.
LMR Partners's ProQR Therapeutics position peaked at $99K in Q1 2022.
51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2022.

Based on LMR Partners's 13F filing for Q2 2022, filed 15 Aug 2022.